Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 771856 · FYE Apr 30 · Prices AT CLOSE 2026-07-30 (USD)
Last $5.26Day −3.66%Mkt cap $73MP/E (FY) 15.9×1Y −17.9%Off 52W high −39.8%Vol (1Y) 61.9%
Split-adj closes · 240 of 2,524 · price rtn
| Short interest0.5% of sh out |
| Days to cover7.8d |
| 13F net flow (QoQ)+0.19% |
| Top-10 13F concentration96.6% |
| Next report (est.)2026-10-26 |
SI 2026-07-15 · 13F 2026-Q1
| P/E (FY)15.9× |
| Sales (TTM)$59.4M |
| Earnings (TTM)-$1.2M |
| Net margin8.3% |
| EPS growth 3Y102.1% |
| Sales growth 3Y5.1% |
FY ratios · TTM sales/earnings (USD)
| YTD−23.9% |
| 1Y−17.9% |
| 3Y−19.1% |
| 5Y−49.7% |
| 10Y+167.7% |
| Since incept. (ann.)+9.0% |
Total return · from 2016-07-11
| Ann. volatility (1Y)61.9% |
| Ann. volatility (3Y)65.9% |
| Sharpe (1Y)−0.02 |
| Sharpe (3Y)0.22 |
| Max drawdown (1Y)−36.6% |
| Max drawdown (3Y)−55.0% |
| Beta (3Y vs SPY)0.25 |
Daily returns, ann.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BATTERY MANAGEMENT CORP. | 2.4M | $14M | 17.44% | +0.0% |
| NEA Management Company, LLC | 1.7M | $10M | 12.34% | +0.0% |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | 319,674 | $2M | 2.30% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 299,520 | $2M | 2.16% | new |
| MORGAN STANLEY | 242,300 | $1M | 1.74% | +5.5% |
| RENAISSANCE TECHNOLOGIES LLC | 145,539 | $836,849 | 1.05% | −6.0% |
| BlackRock, Inc. | 123,900 | $712,425 | 0.89% | +0.9% |
| Mink Brook Asset Management LLC | 111,338 | $640,194 | 0.80% | +38.6% |
Δ vs 2025-Q4
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-04-30 | 2026-07-27 | — | — | $13.8M | +12.0% |
| 2026-01-31 | 2026-03-12 | −$0.02 | −106.5% | $16.6M | −2.8% |
| 2025-10-31 | 2025-12-15 | $0.02 | −60.0% | $15.0M | +11.5% |
| 2025-07-31 | 2025-09-15 | −$0.03 | −133.3% | $14.0M | −0.5% |
As-reported XBRL · next 2026-10-26 est.
Pharmacology Services 96% · Product And Service Other 3% · Translational Oncology Solutions TOSLicense Revenue 1%
product & service · TAGGED revenue
